Payment overview · 2025
General Payments
$231.78
12 reported records · 9 companies
Healthcare provider profile · identity verified
Thomas Harvey Mcculloch, MD
Allopathic & Osteopathic Physicians|Family Medicine · FAIRHOPE, AL · NPI 1750383790
Verified facts
What the public records show
CMS Open Payments records show Thomas Harvey Mcculloch, MD received $231.78 in general payments during 2025 across 12 reported records.
ACADIA Pharmaceuticals Inc accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $43.40 | 18.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.81 | 18.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.52 | 13.2% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $24.05 | 10.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.91 | 9.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.54 | 9.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.82 | 7.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.18 | 7.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.55 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $231.78 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 88 |
| Losartan Potassium | Losartan Potassium | 362 | 94 |
| Potassium Chloride | Potassium Chloride | 275 | 66 |
| Sertraline Hcl | Sertraline Hcl | 264 | 62 |
| Lisinopril | Lisinopril | 251 | 66 |
| Gabapentin | Gabapentin | 250 | 54 |
| Omeprazole | Omeprazole | 232 | 60 |
| Furosemide | Furosemide | 215 | 66 |
| Metformin Hcl | Metformin Hcl | 211 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 51 |
| Trazodone Hcl | Trazodone Hcl | 174 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 51 |
| Donepezil Hcl | Donepezil Hcl | 153 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 39 |
| Eliquis | Apixaban | 126 | 22 |
| Mirtazapine | Mirtazapine | 123 | 24 |
| Baclofen | Baclofen | 120 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 25 |
| Allopurinol | Allopurinol | 119 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 29 |
| Buspirone Hcl | Buspirone Hcl | 105 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 53 |
| Ozempic | Semaglutide | 98 | 22 |
| Olanzapine | Olanzapine | 96 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 38 |
| Alendronate Sodium | Alendronate Sodium | 87 | 17 |
| Simvastatin | Simvastatin | 87 | 29 |
| Tramadol Hcl | Tramadol Hcl | 86 | 30 |
| Carvedilol | Carvedilol | 85 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 31 |
| Montelukast Sodium | Montelukast Sodium | 77 | 25 |
| Finasteride | Finasteride | 69 | 16 |
| Spironolactone | Spironolactone | 68 | 15 |
| Chlorthalidone | Chlorthalidone | 65 | 19 |
| Famotidine | Famotidine | 64 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 19 |
| Memantine Hcl | Memantine Hcl | 63 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 15 |
| Jardiance | Empagliflozin | 55 | 18 |
| Indapamide | Indapamide | 51 | 12 |
| Irbesartan | Irbesartan | 48 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Glipizide Er | Glipizide | 42 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Myrbetriq | Mirabegron | 42 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Torsemide | Torsemide | 26 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 12 |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Atenolol | Atenolol | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $231.78 · 12 records | ACADIA Pharmaceuticals Inc | AIRSUPRA, Auvelity, DAYBUE, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, LEQVIO, LOREEV XR, NUPLAZID, REXULTI, SPRAVATO, TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error